A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms PLUM Follow-up
- Sponsors Janssen Research & Development
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 08 Dec 2017 Planned initiation date changed from 17 Nov 2017 to 5 Jan 2018.
- 09 Nov 2017 New trial record